Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the C...
Brand Name : Gemtesa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 06, 2023
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron
Details : Based on this agreement, Eisai will acquire exclusive development and marketing rights from Kyorin for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.
Brand Name : Gemtesa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 31, 2021
LOOKING FOR A SUPPLIER?
Reset All
